mild to moderate Irritant contact dermatitis of hand. Irritant contact dermatitis
Conditions
Interventions
Intervention 1: Intervention group: Patients apply Mamogel cream (produced by Goldaroo Pharmaceutical Company) topically to the affected area twice daily for two consecutive weeks. Intervention 2: Con
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 65 Years
Inclusion criteria
Inclusion criteria: Individuals aged 12–65 years of both sexes, diagnosed with mild to moderate irritant contact dermatitis of the hands by a dermatologist, based on the Hand Eczema Severity Index (HECSI) classification system Patients who have not received any medical treatment for hand dermatitis for at least one week prior to enrollment, and who have not used topical corticosteroids during the past week. Patients evaluated according to Traditional Persian Medicine principles, with a comprehensive TPM history obtained at the outset of the study. Provision of written informed consent.
Exclusion criteria
Exclusion criteria: Patients reporting a history of allergy to Althaea officinalis Patients currently receiving other corticosteroid medications, antibiotics, or skin-drying agents such as isotretinoin (Roaccutane). Patients unwilling to discontinue use of these medications. Patients with very severe hand dermatitis, with a HECSI (Hand Eczema Severity Index) score above 117, according to the classification system Patients with uncontrolled systemic cardiovascular, respiratory, hematologic, urinary, autoimmune, infectious diseases, or diabetes mellitus. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of dermatitis symptoms. Timepoint: Effect of Mamogel cream after two weeks of use, and assessment of disease recurrence two weeks after discontinuation of the medication. Method of measurement: Severity of dermatitis symptoms is assessed based on patient self-report using the standard Hand Eczema Severity Index (HECSI) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and type of adverse effects observed during treatment. Timepoint: Assessments will be performed at baseline, after completion of treatment, and two weeks after treatment discontinuation. Method of measurement: Based on patient self-report and according to the CTCAE questionnaire.;Quality of life. Timepoint: Assessments will be performed at baseline, after completion of treatment, and two weeks after treatment discontinuation. Method of measurement: Based on patient self-report by completing the standard DLQI questionnaire.;Recurrence of symptoms two weeks after completion of treatment. Timepoint: two weeks after completion of treatment. Method of measurement: Based on patient self-report by completing the standard HECSI questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactzahra sadat akhlaghi
Iran University of Medical Sciences
Outcome results
None listed